As previously shown, HER2 1+ and HER2 0 tumors differ in the expression profile of a number of genes, and clinically, HER2-low (i.e., 1+ and lack of ERBB2 amplification) BC shows more ALN involvement compared to HER2 0 BC [35]. This evidence concerns the gene ERBB2 and breast cancer.